Published in Cancer Cell on June 12, 2012
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell (2014) 5.52
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 1.67
IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature (2014) 1.66
Doxorubicin enhances nucleosome turnover around promoters. Curr Biol (2013) 1.58
p53 Family and Cellular Stress Responses in Cancer. Front Oncol (2014) 1.33
Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta (2013) 1.27
ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ (2014) 1.18
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. EMBO Mol Med (2012) 1.10
Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions. PLoS Genet (2013) 1.08
Smoking, p53 mutation, and lung cancer. Mol Cancer Res (2014) 1.03
Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell (2013) 1.00
p53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression. Oncogene (2013) 1.00
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res (2012) 0.98
NRF2 and p53: Januses in cancer? Oncotarget (2012) 0.98
Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol (2013) 0.97
A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Breast Cancer Res (2014) 0.97
Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. Proc Natl Acad Sci U S A (2016) 0.94
Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS One (2013) 0.91
High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors. Cell Cycle (2013) 0.91
Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget (2015) 0.90
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3. Oncotarget (2016) 0.89
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells. Oncotarget (2012) 0.88
Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer. PLoS One (2012) 0.87
Recent discoveries in the cycling, growing and aging of the p53 field. Aging (Albany NY) (2012) 0.85
Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition. Mol Biol Cell (2015) 0.85
Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo. Cell Death Differ (2014) 0.84
Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy. BMC Cancer (2015) 0.83
Therapeutic targeting of replicative immortality. Semin Cancer Biol (2015) 0.83
Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy. Oncogene (2015) 0.83
eIF2α phosphorylation bypasses premature senescence caused by oxidative stress and pro-oxidant antitumor therapies. Aging (Albany NY) (2013) 0.83
Proteomic analysis reveals a role for Bcl2-associated athanogene 3 and major vault protein in resistance to apoptosis in senescent cells by regulating ERK1/2 activation. Mol Cell Proteomics (2014) 0.83
Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy. Oncotarget (2015) 0.81
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther (2015) 0.81
p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints. Mol Cancer Res (2014) 0.81
Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels. Cell Stress Chaperones (2012) 0.80
A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget (2015) 0.80
Prognostic significance of p53 immunoexpression in the survival of oral squamous cell carcinoma patients treated with surgery and neoadjuvant chemotherapy. Oncol Lett (2013) 0.80
Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma. Cell Death Differ (2015) 0.79
TP53 drives invasion through expression of its Δ133p53β variant. Elife (2016) 0.79
p53 is a key regulator for osthole-triggered cancer pathogenesis. Biomed Res Int (2014) 0.79
Senescence and cancer: An evolving inflammatory paradox. Biochim Biophys Acta (2015) 0.79
Chemosensitivity and p53; new tricks by an old dog. Breast Cancer Res (2012) 0.78
Nucleolar repression facilitates initiation and maintenance of senescence. Cell Cycle (2015) 0.77
Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis. Oncotarget (2015) 0.77
Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance. Oncotarget (2016) 0.77
EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis. Oncoscience (2016) 0.77
Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. Oncotarget (2015) 0.77
The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line. Bosn J Basic Med Sci (2016) 0.77
Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. Cell Cycle (2016) 0.77
p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells. Mol Cell Biol (2015) 0.76
Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci Rep (2014) 0.76
p53 and DNA methylation suppress the TRAIN to cell death. Cell Cycle (2012) 0.76
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities. Oncotarget (2016) 0.76
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO Mol Med (2016) 0.75
Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. Sci Rep (2017) 0.75
Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines. Oncotarget (2016) 0.75
IL-15 enhances the antitumor effect of human antigen-specific CD8(+) T cells by cellular senescence delay. Oncoimmunology (2016) 0.75
TNBC invasion: downstream of STAT3. Oncotarget (2017) 0.75
Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells. Cancer Biol Ther (2016) 0.75
Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer. PLoS One (2017) 0.75
Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer (2013) 0.75
Che-ating death: CHE1/AATF protects from p53-mediated apoptosis. EMBO J (2012) 0.75
Blocking the utilization of glucose induces the switch from senescence to apoptosis in pseudolaric acid B-treated human lung cancer cells in vitro. Acta Pharmacol Sin (2017) 0.75
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell (1995) 12.39
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22
Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (1995) 8.53
Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A (2001) 7.93
Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell (2008) 6.84
p53 status and the efficacy of cancer therapy in vivo. Science (1994) 6.72
p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res (1995) 6.66
Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell (1988) 6.48
Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest (1999) 6.13
Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science (1997) 4.97
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
The role of apoptosis in cancer development and treatment response. Nat Rev Cancer (2005) 4.19
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
A subset of p53-deficient embryos exhibit exencephaly. Nat Genet (1995) 3.24
DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res (2002) 3.22
Cell-cycle arrest versus cell death in cancer therapy. Nat Med (1997) 3.18
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev (1995) 2.41
Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene (1999) 2.34
Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene (2004) 2.34
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene (2004) 2.30
Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol (2002) 2.13
p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun (2005) 2.03
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res (2006) 1.75
Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol (2004) 1.64
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
p53 mutations occur in aggressive breast cancer. Cancer Res (1992) 1.43
CXCL5 promotes prostate cancer progression. Neoplasia (2008) 1.37
Cytokine expression and signaling in drug-induced cellular senescence. Oncogene (2009) 1.34
p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene (2009) 1.29
TP53 status and response to chemotherapy in breast cancer. Pathobiology (2008) 1.28
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet (2002) 1.26
A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer (2003) 1.18
Chemokine networks and breast cancer metastasis. Breast Dis (2007) 1.17
Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol (2006) 1.16
Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol (2010) 1.15
Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene (2000) 1.14
Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas (2000) 1.13
Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer (2006) 1.10
p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer (2009) 1.01
Effect of fixation and epitope retrieval on BrdU indices in mammary carcinomas. J Histochem Cytochem (2000) 0.99
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist (2010) 0.97
p53 protein overexpression and chemosensitivity in breast cancer. Lancet (1995) 0.86
p53 protein overexpression and chemosensitivity in breast cancer. Institut Gustave-Roussy Breast Cancer Group. Lancet (1995) 0.85
Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis. Mol Cell Endocrinol (2001) 0.82
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- and interchromosomal interactions. Nat Genet (2006) 8.99
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 6.82
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev (2007) 5.83
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res (2003) 4.29
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis (2015) 3.94
Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med (2011) 3.74
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
Poly(ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation. Nat Genet (2004) 3.56
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol (2003) 3.54
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 3.50
Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell (2003) 3.42
Uniqueness theorems in bioluminescence tomography. Med Phys (2004) 3.32
The draft genome of a diploid cotton Gossypium raimondii. Nat Genet (2012) 3.18
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol (2005) 2.97
The genetic map of Artemisia annua L. identifies loci affecting yield of the antimalarial drug artemisinin. Science (2010) 2.92
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
Treatment of neural injury with marrow stromal cells. Lancet Neurol (2002) 2.89
MDM2, an introduction. Mol Cancer Res (2003) 2.87
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 2.83
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer (2013) 2.69
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem (2002) 2.68
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab (2005) 2.65
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet (2010) 2.62
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res (2003) 2.61
A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol (2012) 2.54
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
CD4-CD8 lineage commitment is regulated by a silencer element at the ThPOK transcription-factor locus. Immunity (2008) 2.49
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet (2009) 2.45
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology (2002) 2.38
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Arabidopsis ABA INSENSITIVE4 regulates lipid mobilization in the embryo and reveals repression of seed germination by the endosperm. Plant Cell (2006) 2.27
Principled sure independence screening for Cox models with ultra-high-dimensional covariates. J Multivar Anal (2012) 2.23
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells (2012) 2.14
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.14
Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res (2006) 2.13
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol (2005) 2.11
Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab (2006) 2.10
Spatial cluster detection for censored outcome data. Biometrics (2007) 2.07
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A (2006) 2.03
Multispectral optical imaging device for in vivo detection of oral neoplasia. J Biomed Opt (2008) 2.03
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention (2013) 2.02
NaBC1 is a ubiquitous electrogenic Na+ -coupled borate transporter essential for cellular boron homeostasis and cell growth and proliferation. Mol Cell (2004) 2.02
Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum (2008) 2.01
Genetic bio-ancestry and social construction of racial classification in social surveys in the contemporary United States. Demography (2014) 2.00
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
A Papaver somniferum 10-gene cluster for synthesis of the anticancer alkaloid noscapine. Science (2012) 2.00
TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med (2008) 1.99
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther (2010) 1.99
Overexpression of Separase induces aneuploidy and mammary tumorigenesis. Proc Natl Acad Sci U S A (2008) 1.98
Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem (2001) 1.97
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells (2008) 1.96
Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. Nat Genet (2011) 1.95
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Parental decision making about the HPV vaccine. Cancer Epidemiol Biomarkers Prev (2010) 1.94
Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol (2002) 1.94
14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol (2003) 1.93
Transcriptome analysis of root transporters reveals participation of multiple gene families in the response to cation stress. Plant J (2003) 1.93
NF-kappa B-inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. J Immunol (2004) 1.92
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab (2007) 1.89
A simple, rapid, high-fidelity and cost-effective PCR-based two-step DNA synthesis method for long gene sequences. Nucleic Acids Res (2004) 1.86
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab (2013) 1.85
Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production. J Neurosci Res (2002) 1.85
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol (2007) 1.85
Residential exposure to petrochemicals and the risk of leukemia: using geographic information system tools to estimate individual-level residential exposure. Am J Epidemiol (2006) 1.84
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood (2009) 1.82
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (2009) 1.82
Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences. Cell (2012) 1.81